Pharmacokinetics Services

Pharmacokinetics Services

Global Pharmacokinetics Services Market to Reach US$1.6 Billion by 2030

The global market for Pharmacokinetics Services estimated at US$1.0 Billion in the year 2023, is expected to reach US$1.6 Billion by 2030, growing at a CAGR of 6.5% over the analysis period 2023-2030. Small Molecules, one of the segments analyzed in the report, is expected to record a 6.1% CAGR and reach US$1.2 Billion by the end of the analysis period. Growth in the Large Molecules segment is estimated at 7.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$271.9 Million While China is Forecast to Grow at 6.1% CAGR

The Pharmacokinetics Services market in the U.S. is estimated at US$271.9 Million in the year 2023. China, the world`s second largest economy, is forecast to reach a projected market size of US$249.2 Million by the year 2030 trailing a CAGR of 6.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 5.8% and 5.4% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Pharmacokinetics Services Market – Key Trends & Drivers Summarized

Why Are Pharmacokinetics Services Crucial in Drug Development?

Pharmacokinetics services are a fundamental component of the drug development process, playing a critical role in understanding how a drug moves through the body—its absorption, distribution, metabolism, and excretion (ADME). These services provide insights into the drug’s behavior, helping researchers determine the optimal dosage, frequency, and delivery method for therapeutic efficacy. The data generated from pharmacokinetics studies are crucial for ensuring the safety and effectiveness of new drugs before they reach clinical trials and, eventually, the market. Through detailed analysis, pharmacokinetics services assess how long a drug remains active in the system, how it is broken down in the liver, and how efficiently it is eliminated, all of which are vital for minimizing side effects and maximizing patient outcomes.

In the highly competitive pharmaceutical industry, pharmacokinetics services help reduce the risk of late-stage drug failures by identifying potential issues early in the development cycle. These services are particularly critical for drugs with narrow therapeutic windows, where precise dosing is essential to avoid toxicity or ineffective treatment. By providing a detailed map of the drug’s journey through the body, pharmacokinetics services allow for more informed decision-making in the design of clinical trials, ultimately improving the likelihood of successful regulatory approval.

How Are Technological Advancements Shaping the Pharmacokinetics Services Market?

The integration of cutting-edge technologies has transformed pharmacokinetics services, enhancing their precision, speed, and scalability. One of the most significant advancements is the use of high-throughput screening (HTS) technologies, which allow for the rapid assessment of multiple drug candidates simultaneously. HTS, combined with advanced computational models, enables more efficient prediction of a drug’s pharmacokinetics profile at earlier stages of development, reducing the need for extensive in-vivo studies and accelerating the timeline for candidate selection. Moreover, the application of artificial intelligence (AI) and machine learning (ML) has revolutionized data analysis in pharmacokinetics. AI algorithms can analyze vast datasets from pharmacokinetics studies to predict a drug’s behavior in various patient populations, offering insights that go beyond traditional statistical methods. These technologies also aid in identifying patterns that may indicate potential drug-drug interactions or adverse effects. AI-driven pharmacokinetics modeling has the potential to significantly reduce costs and time associated with drug development, allowing for more precise dosing regimens and personalized medicine approaches. Furthermore, advancements in bioanalytical techniques, such as mass spectrometry and liquid chromatography, have improved the sensitivity and accuracy of pharmacokinetics studies. These technologies allow researchers to detect and quantify drug concentrations in biological samples with greater precision, providing a more detailed understanding of how a drug is metabolized and excreted. The growing use of these technologies in pharmacokinetics services is driving the industry toward more robust and reliable data collection, which is essential for regulatory submissions and clinical trial design.

How Is Outsourcing of Pharmacokinetics Services Influencing the Market?

The outsourcing of pharmacokinetics services to specialized contract research organizations (CROs) has become a prevalent trend, as pharmaceutical and biotechnology companies look to streamline their drug development pipelines. Outsourcing allows companies to access the latest technologies, expertise, and infrastructure without the need for significant internal investments. This trend is particularly strong among small to mid-sized pharmaceutical companies, which may lack the resources to conduct in-house pharmacokinetics studies.

By partnering with CROs, these companies can take advantage of specialized pharmacokinetics services that are equipped with state-of-the-art bioanalytical tools and staffed by experts in drug metabolism and pharmacokinetics (DMPK). Outsourcing also offers the flexibility to scale services up or down based on the needs of individual drug development programs, making it a cost-effective solution for both early-stage and late-stage drug candidates. Additionally, the global reach of many CROs allows pharmaceutical companies to conduct pharmacokinetics studies across multiple geographic regions, which is crucial for addressing regulatory requirements in different markets.

Another key driver of outsourcing is the increasing complexity of new drug candidates, particularly in areas such as biologics, gene therapies, and personalized medicines. These complex therapeutics require highly specialized pharmacokinetics services, which CROs are well-positioned to provide. The rise of personalized medicine, in particular, is driving demand for pharmacokinetics studies that focus on individual variability in drug metabolism, distribution, and excretion, further fueling the growth of the outsourcing market.

What Are the Key Drivers of Growth in the Pharmacokinetics Services Market?

Growth in the pharmacokinetics services market is driven by several factors, including technological innovations, increasing complexity in drug development, and the rising trend of outsourcing. One of the primary drivers is the growing demand for personalized medicine, where pharmacokinetics studies are essential for understanding how individual genetic differences affect drug metabolism. This trend has expanded the market for pharmacokinetics services, as pharmaceutical companies require more precise and individualized data to support personalized treatment regimens. Additionally, the increasing prevalence of biologics and biosimilars in the pharmaceutical pipeline has driven demand for advanced pharmacokinetics services. These complex molecules have unique pharmacokinetics profiles, requiring specialized analysis that goes beyond traditional small-molecule drugs. As more biologics enter clinical development, the need for tailored pharmacokinetics studies will continue to grow, particularly for therapies targeting oncology, autoimmune diseases, and rare genetic disorders. The expansion of global clinical trials has also contributed to the growth of the pharmacokinetics services market. As pharmaceutical companies seek to bring drugs to market in multiple regions, they must comply with diverse regulatory requirements, necessitating region-specific pharmacokinetics data. This has led to increased demand for CROs that can conduct multi-regional studies and provide comprehensive pharmacokinetics data across various patient populations. Lastly, the regulatory landscape continues to evolve, with agencies such as the FDA and EMA placing greater emphasis on pharmacokinetics data in drug approval processes. This has driven pharmaceutical companies to invest more heavily in pharmacokinetics studies to ensure regulatory compliance and minimize the risk of late-stage clinical failures. The growing complexity of regulatory requirements, particularly for novel therapies, is expected to further propel the demand for high-quality pharmacokinetics services.

Select Competitors (Total 34 Featured) -

• Biologics Consulting Group, Inc.
• Certara L.P.
• Charles River Laboratories International, Inc.
• Creative Bioarray
• Eurofins Scientific, Inc.
• Evotec AG
• Frontage Labs
• GVK Biosciences Private Limited
• LGC Limited
• Pacific BioLabs
• Parexel International Corporation
• Pharmaceutical Product Development, LLC
• Product Development, LLC (Jaguar Holding Company I, LLC)
• SGS SA
• Shanghai Medicilon Inc.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.